Biocon Reports Strong Revenue Growth in Q4 2022-23, Net Profit Rises 31% to Rs 313 Cr, Revenue Up 57%

Biocon Reports Strong Revenue Growth in Q4 2022-23, Recommends Dividend; Net Profit Declines for the Full Financial Year

Bengaluru-based biotech firm Biocon has reported a significant increase in its fourth-quarter net profit for the fiscal year 2022-23, showcasing strong financial performance. The company’s net profit rose by 31%, reaching Rs 313 crore compared to Rs 239 crore during the same period in the previous fiscal year.

Biocon’s revenue from operations also witnessed substantial growth during the fourth quarter. The company reported a revenue of Rs 3,774 crore, reflecting a remarkable 57% increase compared to Rs 2,409 crore generated in the corresponding quarter of the previous financial year.

However, for the entire financial year, Biocon experienced a decline in net profit. The net profit stood at Rs 462.7 crore, representing a decrease of 29% from the previous year’s figure of Rs 648.4 crore in 2021-22.

The impressive performance in the fourth quarter can be attributed to Biocon’s strategic initiatives and operational efficiency. The company’s focus on innovation, research, and development has allowed it to capitalize on market opportunities and deliver favorable financial results.

Siddharth Mittal, CEO and Managing Director of Biocon, expressed his satisfaction with the company’s Q4 performance. He highlighted that the robust net profit growth demonstrates Biocon’s ability to drive profitability amidst a challenging business environment. He further emphasized the company’s commitment to delivering high-quality, affordable healthcare solutions and creating long-term value for stakeholders.

Biocon’s positive financial performance can be attributed to its diverse portfolio of products and services, including biopharmaceuticals, biosimilars, and research services. The company’s relentless focus on innovation and customer-centricity has helped it gain a strong foothold in the biotechnology sector.

Looking ahead, Biocon aims to strengthen its position as a global biotech leader by investing in research and development, expanding its product portfolio, and exploring strategic collaborations. The company remains committed to addressing unmet medical needs and contributing to the advancement of healthcare globally.

During the January to March quarter of 2022-23, Biocon’s revenue from operations surged by 57% to Rs 3,774 crore, compared to Rs 2,409 crore generated in the same quarter of the previous financial year. This impressive growth can be attributed to the company’s effective business strategies and market expansion efforts.

The company’s board has recommended a final dividend of 30% or Rs. 1.50 per equity share with a face value of Rs 5 each for the financial year ended March 31, 2023, pending shareholders’ approval. This reflects Biocon’s commitment to rewarding its shareholders and sharing its success.

However, for the entire financial year, Biocon experienced a decline in net profit. The net profit stood at Rs 462.7 crore, indicating a decrease of 29% compared to the previous year’s figure of Rs 648.4 crore in 2021-22. This decline was primarily due to exceptional items, which amounted to Rs 219 crore. Notably, these exceptional items were associated with the deal-related expenses of the Viatris transaction.

Despite the decline in net profit, Biocon reported a substantial 86% increase in revenue from operations for the full financial year. The revenue reached Rs 1,117 crore, surpassing the previous year’s figure of Rs 8,184 crore in 2021-22. This highlights the company’s ability to generate revenue growth and expand its market presence.

Siddharth Mittal, CEO and Managing Director of Biocon, acknowledged the challenges faced during the financial year and expressed confidence in the company’s long-term growth prospects. He emphasized the continued focus on driving innovation, research, and development to create sustainable value for shareholders and contribute to the healthcare sector.

Biocon’s diverse portfolio of products and services, including biopharmaceuticals and research services, positions the company as a key player in the biotechnology industry. The company’s commitment to expanding its product offerings and exploring strategic partnerships remains crucial to its growth strategy.

Looking ahead, Biocon aims to leverage its capabilities and capitalize on emerging opportunities in the biotech sector. By investing in research and development and pursuing strategic collaborations, the company aspires to address unmet medical needs and further strengthen its market position.

“FY23 has been a transformational year led by the acquisition of our partnered biosimilars business from Viatris, which has significantly contributed to Biocon’s robust consolidated financials. We ended FY23 with a strong Q4 performance where revenues grew, and EBITDA also increased by 75% to Rs 1,152 crore. Biosimilars continue to be the largest business segment for Biocon, with revenues of Rs 2,102 crore, a growth of 114%, exiting the year on a $1 billion revenue trajectory,” said Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics.

Biosimilars, a key focus area for Biocon, continued to drive substantial revenue growth, emerging as the company’s largest business segment. The biosimilars division generated revenues of Rs 2,102 crore, representing an impressive growth rate of 114%. This remarkable performance positions Biocon’s biosimilars business on a trajectory towards achieving $1 billion in revenue.

Kiran Mazumdar-Shaw, the Executive Chairperson of Biocon and Biocon Biologics, expressed her satisfaction with the company’s achievements during FY23. The acquisition of the biosimilars business and its subsequent contributions to the financials highlight the success of Biocon’s strategic decisions and its commitment to driving innovation in the biotech industry.

As the comapny continues to expand its portfolio and explore new avenues, the biosimilars business remains a key driver of growth. By leveraging its expertise in biosimilar development and manufacturing, Biocon aims to address unmet medical needs and create significant value for patients and healthcare providers worldwide.

The strong performance in FY23 positions the company for continued success in the biotech sector. With a focus on research and development, strategic partnerships, and the pursuit of innovation, the company is well-positioned to seize emerging opportunities and contribute to advancements in healthcare.

In conclusion, Biocon’s transformative year in FY23, driven by the acquisition of the biosimilars business, has propelled the company’s financial performance. With strong revenue growth and a significant increase in EBITDA, Biocon is poised for further expansion and success in the biotech industry under the leadership of Kiran Mazumdar-Shaw.